【Press Release】 12 April 2018

ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

（Stock Code：1061）

Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops

Hong Kong, 12 April 2018 －－ ESSEX BIO-TECHNOLOGY LIMITED ("EssexBio" or the "Group"－Stock code: 1061) is pleased to announce that Zhuhai Essex Bio-Pharmaceutical Co.,Ltd, an indirectly wholly-owned subsidiary of the Group, has successfully obtained a Certificate of Good Manufacturing Practices for Pharmaceutical Products ("GMP Certificate") in respect of the preservative-free single-dose Tobramycin Eye Drops issued by Guangdong Provincial Food and Drug Administration, which is valid up to 29 March 2023.

The preservative-free single-dose Tobramycin Eye Drops was approved from China Food and Drug Administration ("CFDA") in June 2017. With the GMP Certificate, the Group will launch its Tobramycin Eye Drops in the second quarter of 2018.

In China, Tobramycin Eye Drops has been extensively used for the treatment of various eye infections. Following the approval for production, EssexBio will be the first company to commercialise the preservative-free single-dose Tobramycin Eye Drops in China. There are eight more preservative-free single-dose ocular drugs in different clinical stages of development, which are expected to obtain approval from CFDA for commercialisation in the coming years.

The Board of Directors of EssexBio expects with confidence that the launch of the preservative-free single-dose Tobramycin will enrich the Group's ocular product portfolios and thus strengthen its market position in China prescription ocular drugs.

-END-

About EssexBio

Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90's, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration.

The Company currently has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by CFDA as Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively. Beifuji is the first in the world to have obtained approval from CFDA for commercialisation in 1998.

The Company focuses on two main therapeutics; Ophthalmology and Surgical arena of topical (skin) surface wounds, which primarily covers Dermatology, Stomatology and Obstetrics & Gynaecology, while selectively pursuing therapeutics in Neurology, Oncology and Orthopaedics. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of projects are on unit dose for Ophthalmic and Respiratory disease.

The Company's products and its 3rd party products are marketed and sold through more than 5,400 hospitals in China and are managed directly by its 39 regional sales offices with about 1,410 sales and marketing people. Its 3rd party products; notably are inclusive of Xalacom eye drops and Xalatan eye drops of Pfizer (for Ophthalmology), Iodized Lecithin Capsules (for Ophthalmology), Yi Xue An Granules (for Obstetrics & Gynaecology) and Carisolv Products (for Stomatology).

This press release is issued by Zhixin Investor Relations Consultant Limited on behalf of **Essex Bio-Technology Limited.**

For further information, please contact:
Zhixin Investor Relations Consultant Limited
Ms. Tan Ronghua
Tel: 0755 8323 9767
E-mail: tanronghua@zhixincaijing.com